Chi­nese biotech start­up adds $315M to the bank af­ter bring­ing 5 Take­da drugs to its fold

More than two years af­ter ar­riv­ing on the Chi­na bio­phar­ma scene with a $322 mil­lion deal for five of Take­da’s drugs, Has­ten Bio­phar­ma has land­ed $315 mil­lion to fu­el fu­ture ac­qui­si­tions.

CBC Group, the in­vest­ment firm that helped put the com­pa­ny to­geth­er, is once again head­lin­ing the round, joined by Abu Dhabi sov­er­eign wealth fund Mubadala in co-lead­ing a line­up of in­sti­tu­tion­al in­vestors.

Has­ten is based in Hefei, a five-hour dri­ve to the east from Chi­na’s biotech hub in Shang­hai, and ac­cord­ing to its web­site, has built a team of more than 700 peo­ple since launch­ing in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER